Pharmaceutical

Ipsen gains global rights to Foreseen Biotech’s FS001 ADC

Ipsen has entered an exclusive global licensing agreement with Foreseen Biotech for FS001, a potentially first-in-class ADC.

Jul 14, 2024 - 04:00
Ipsen gains global rights to Foreseen Biotech’s FS001 ADC
Ipsen has entered an exclusive global licensing agreement with Foreseen Biotech for FS001, a potentially first-in-class ADC.
Read the original article

Tags:

Previous Article

NHS rolls out “more convenient” Ocrevus injection for multiple sclerosis

Next Article

FDA grants fast track designation to AskBio’s AB-1005 for PD

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Amgen’s rheumatoid arthritis drug Enbrel targeted for first-in-the-nation price limit in Colorado

STAT+: Amgen’s rheumatoid arthritis drug Enbrel targete...

Feb 23, 2024

STAT+: Dana-Farber CEO on Mass General split: Boston needed a dedicated cancer hospital

STAT+: Dana-Farber CEO on Mass General split: Boston ne...

Oct 10, 2023

UBC to bolster safety functions with Oracle’s cloud technology

UBC to bolster safety functions with Oracle’s cloud tec...

Aug 2, 2023